Analyst coverage from Bell Potter Securities, Maxim Group and H.C.Wainwright & CoDear Investors,Three independent equity research analysts have published on Kazia over the past week – all reiterating
BUY recommendations.Research by Bell Potter Securities, Maxim Group, and H.C. Wainwright & Co follows the release of
positive final phase 2 clinical trial results for paxalisib, our lead drug for the treatment of the deadly brain cancer, glioblastoma (GBM).
Latest Research:3 Dec - Maxim Group analyst Naureen Quibria reiterated a
BUY recommendation with a 12 month Price Target of US$ 18.00. To view the report, please click
here.6 Dec - Bell Potter analyst John Hester rated Kazia with a
BUY recommendation (Speculative risk rating) with a 12 month
Price Target of AU$ 2.40. To view the report, please click
here.7 Dec - H.C.Wainwright & Co analyst Sean Lee reiterated a BUY recommendation with a 12 month Price Target of US$ 17.00. To view the report, please click
here.The pivotal study for paxalisib, GBM AGILE, commenced recruitment in January 2021 and recently opened in Canada. Expansion to Europe and China is expected in 2022. Seven other clinical trials of paxalisib in different forms of brain cancer are ongoing, and multiple additional data readouts are expected in 2022.Once more, we would like to extend our gratitude to all of our shareholders for your continued support and we would like to wish you all a very happy and safe festive season!Kind regards, Kazia Investor Relations
